Hemostemix (CVE:HEM) Shares Down 5.3% – Here’s Why

Hemostemix Inc. (CVE:HEM)’s share price was down 5.3% during mid-day trading on Monday . The stock traded as low as C$0.09 and last traded at C$0.09. Approximately 292,378 shares traded hands during trading, a decline of 4% from the average daily volume of 304,560 shares. The stock had previously closed at C$0.10.

Hemostemix Stock Performance

The company has a debt-to-equity ratio of -55.07, a quick ratio of 0.48 and a current ratio of 0.04. The company has a market capitalization of C$15.08 million, a P/E ratio of -2.96 and a beta of 1.01. The company’s fifty day simple moving average is C$0.09 and its 200-day simple moving average is C$0.11.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.